# Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide

> **NCT07713992** · NA · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University** · enrollment: 72 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)
- Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus

## Interventions

- **DRUG:** Mazdutide(Dual GLP-1R/GCGR Agonist)
- **DRUG:** Semaglutide (1 Mg Dose)

## Key facts

- **NCT ID:** NCT07713992
- **Lead sponsor:** Tianjin Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-15
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-02-01
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-07-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07713992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07713992, "Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07713992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*